Cerecor is a biopharmaceutical company. The company is building a pipeline of therapies in neurology, pediatric healthcare, and orphan rare diseases. The company's neurology pipeline is led by CERC-301, which is in a Phase I safety study for Neurogenic Orthostatic Hypotension. The company is also developing two other neurological clinical and preclinical stage compounds. The company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. All three of these compounds are preclinical therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation by means of substrate replacement therapy.

Christopher & Banks is a specialty retailer featuring women's apparel and accessories. The company's merchandise assortments include women's apparel, consisting of casual clothing, everyday basics, wear-to-work, leisure / active wear, and seasonal sleepwear in missy, petite and women sizes. The company's Christopher and Banks (CB) stores provides merchandise assortments in women's apparel and accessories for missy and petite sizes. The company's C.J. Banks (CJ) stores provides merchandise assortments in women's apparel and accessories for women's sizes. The company's Missy, Petite, Women and outlet stores, and its website provides merchandise assortments from both CB and CJ in all three ranges.

General Finance is a holding company. Through its subsidiaries, the company is a rental services company providing portable storage, modular space and liquid containment solutions. The company's branch locations across North America and the Asia-Pacific provide a range of portable storage units, including its steel containers, office container, mobile office and modular space products and steel tanks that provide the company's customers a way to meet their temporary storage and space needs. The company's customers use its storage and space units for a variety of applications, including the temporary storage of materials, supplies, equipment, retail merchandise inventories, documents and liquid storage and for office use.

Macquarie Infrastructure is a holding company. The company owns and operates a portfolio of businesses that provide services to other businesses, government agencies and individuals primarily in the U.S. The businesses the company owns and operate are: International-Matex Tank Terminals, which provides bulk liquid terminalling services to third parties in the U.S. and in Canada; Atlantic Aviation, which provides fuel, terminal, aircraft hangaring and other services primarily to owners and operators of general aviation jet aircraft at airports throughout the U.S.; and MIC Hawaii, which consist of energy company that processes and distributes gas and provides related services.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

ViaSat is a provider of broadband technologies and services. The company conducts its business through three segments: satellite services, which provides satellite-based broadband services to consumers, enterprises, and mobile broadband customers; commercial networks, which develops and produces a variety of satellite and wireless products, systems and solutions that enable the provision of fixed and mobile broadband services; and government systems, which provides global mobile broadband services to military and government users, and develops and produces network-centric Internet Protocol-based fixed and mobile communications products and solutions.

Vical researches and develops biopharmaceutical products, including those based on the company's patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. The company has three active development programs in the area of infectious disease comprised of: HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; antifungal VL-2397 for the treatment of patients with invasive aspergillosis; and an ongoing early stage development program of a treatment for chronic hepatitis B virus infection based on its DNA and lipid-delivery technologies.